论文部分内容阅读
目的:观察厄贝沙坦联合丹参川穹嗪治疗糖尿病肾病(DN)的疗效。方法:76例DN患者随机分为2组,对照组口服厄贝沙坦150 mg,qd,疗程12周;治疗组在对照组基础上加用丹参川芎嗪注射液10 ml,qd,14 d为1疗程。观察2组疗效及治疗前后血压、血尿素氮(BUN)、血清肌酐(Scr)、三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、尿微量白蛋白排泄率(UAER)等指标的变化。结果:治疗后,两组SBP和DBP均较治疗前下降(P<0.05),且治疗组下降更明显(P<0.05).两组治疗后BUN、Scr和UAER均明显降低(P<0.01),治疗组BUN、Scr和UAER降低更为明显(P<0.05)。治疗组治疗后TG、TC、LDL-C、HDL-C均较治疗前有显著变化(P<0.01),而对照组无上述变化(P<0.05)。治疗组总有效率89.47%明显高于对照组的65.79%(P<0.05)。结论:厄贝沙坦联合丹参川芎嗪治疗DN可以降低血压,减少蛋白尿,降低TG、TC、UAER,增加HDL-C,稳定肾功能,疗效优于单用厄贝沙坦,是治疗DN的较好组合。
Objective: To observe the curative effect of irbesartan and salvianolate on diabetic nephropathy (DN). Methods: 76 patients with DN were randomly divided into two groups. The control group was treated with irbesartan 150 mg qd for 12 weeks. The treatment group was given 10 ml Salviae Miltiorrhizae ligustrazine injection on the basis of the control group, qd, 14 d 1 course of treatment. Blood pressure, blood urea nitrogen (BUN), serum creatinine (Scr), triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), urine microalbumin Excretion rate (UAER) and other indicators of change. Results: After treatment, SBP and DBP in both groups decreased significantly (P <0.05), and the treatment group decreased more obviously (P <0.05) .BUN, Scr and UAER decreased significantly after treatment in both groups (P <0.01) , The treatment group BUN, Scr and UAER decreased more significantly (P <0.05). The levels of TG, TC, LDL-C and HDL-C in the treatment group after treatment were significantly different from those before treatment (P <0.01), but not in the control group (P <0.05). The total effective rate in the treatment group was 89.47%, which was significantly higher than that in the control group (65.79%, P <0.05). Conclusion: Irbesartan combined with Salvia miltiorrhizae tetramethylpyrazine treatment of DN can reduce blood pressure, reduce proteinuria, reduce TG, TC, UAER, increase HDL-C, stable renal function, the effect is better than single irbesartan, is the treatment of DN Better combination.